About This Deal

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. acquired PathoQuest SAS for EUR 51.6 million (approximately $60.0 million), a transaction announced in January 2026, structured as option exercise for remaining ~79% equity interest (cash and Credit Facility proceeds).

PathoQuest SAS operates in Manufacturing. Provider of next-generation-sequencing-based biosafety and viral testing services; Charles River exercised its option to acquire the remaining approximately 79% equity interest.

Strengthens Charles River's biologics testing and biosafety capabilities within its Manufacturing segment.

Deal Terms

Acquirer
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Target
PathoQuest SAS
Value
EUR 51.6 million (approximately $60.0 million)
Date
January 2026
Type
Acquisition
Status
Ready

Transaction Details

Segment
Manufacturing
Structure
Option exercise for remaining ~79% equity interest (cash and Credit Facility proceeds)
Announced
January 9, 2026

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: SEC filing ↗

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.